Puma Biotechnology (PBYI) Non-Current Assets (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Non-Current Assets data on file, last reported at $50.4 million in Q1 2026.

• Quarterly Non-Current Assets fell 20.78% year-over-year to $50.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.7 million (down 14.91% YoY) and the FY2025 annual result came in at $53.6 million, down 18.36% from the prior year.
• Non-Current Assets fell to $50.4 million in Q1 2026, from $53.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $87.8 million in Q4 2022 to a low of $50.4 million in Q1 2026.
• A 5-year average of $70.5 million and a median of $71.1 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets climbed 3.24% — and 2026, when it decreased 20.78%.
• Tracing PBYI's Non-Current Assets over 5 years: stood at $87.8 million in 2022, then retreated by 15.31% to $74.3 million in 2023, then slipped by 11.66% to $65.7 million in 2024, then dropped by 18.36% to $53.6 million in 2025, then retreated by 5.92% to $50.4 million in 2026.
• The last three Non-Current Assets figures came in at $50.4 million (Q1 2026), $53.6 million (Q4 2025), and $59.3 million (Q3 2025), per Business Quant data.